Striatal pathology underlies prion infection-mediated hyperactivity in mice

Prion

Volumn 4, Issue 4, 2010, Pages 302-315

  Gunapala, Keith M ^a   Chang, Daniel ^a   Hsu, Cynthia T ^a   Manaye, Kebreten ^b   Drenan, Ryan M ^a   Switzer, Robert C ^c   Steele, Andrew D ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Neuroscience Associates Inc   (United States)

Author keywords

Home cage; Neurodegeneration; Protein misfolding; PrP; Transmissible spongiform encephalopathy

Indexed keywords

ACETYLCHOLINE; BIOLOGICAL MARKER; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NORADRENALIN; PRION PROTEIN; PROTEIN; PROTEIN IBA1; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; GLIOSIS; HISTOPATHOLOGY; HYPERACTIVITY; MESENCEPHALON; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRION DISEASE; SEROTONINERGIC SYSTEM; STAINING;

ANIMALS; BEHAVIOR, ANIMAL; CHOLINE; GAMMA-AMINOBUTYRIC ACID; GLIOSIS; HOMEOSTASIS; HYPERKINESIS; LOCUS COERULEUS; LONGEVITY; MESENCEPHALON; MICE; NEOSTRIATUM; NERVE DEGENERATION; NEURAL INHIBITION; NEURONS; PARVALBUMINS; PRION DISEASES; PRIONS; SEROTONIN; SUBSTANTIA NIGRA; TIME FACTORS;

MURINAE; MUS;

EID: 78650185885     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.4.4.13721     Document Type: Article

References (60)

1. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010; 9:237-48.
2. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89:1105-52.
3. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-83.
4. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216:136-44.
5. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327:1132-5.
6. Jackson WS, Borkowski AW, Faas H, Steele AD, King OD, Watson N, et al. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron 2009; 63:438-50.
7. Sigurdson CJ, Nilsson KP, Hornemann S, Heikenwalder M, Manco G, Schwarz P, et al. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci USA 2009; 106:304-9.
8. Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 2007; 8:552-61.
9. Morales R, Abid K, Soto C. The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta 2007; 1772:681-91. (Pubitemid 46887653)
10. Steele AD, Hetz C, Yi CH, Jackson WS, Borkowski AW, Yuan J, et al. Prion pathogenesis is independent of caspase-12. Prion 2007; 1:243-7.
11. Steele AD, King OD, Jackson WS, Hetz CA, Borkowski AW, Thielen P, et al. Diminishing apoptosis by deletion of Bax or overexpression of Bcl-2 does not protect against infectious prion toxicity in vivo. J Neurosci 2007; 27:13022-7. (Pubitemid 350159568)
12. Steele AD, Hutter G, Jackson WS, Heppner FL, Borkowski AW, King OD, et al. Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. Proc Natl Acad Sci USA 2008; 105:13626-31.
13. Chen D, Steele AD, Hutter G, Bruno J, Govindarajan A, Easlon E, et al. The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 2008; 43:1086-93.
14. -/- mice. J Virol 2008; 82:12464-71.
15. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008; 105:10238-43.
16. Khurgel M, Switzer RC, 3rd, Teskey GC, Spiller AE, Racine RJ, Ivy GO. Activation of astrocytes during epileptogenesis in the absence of neuronal degeneration. Neurobiol Dis 1995; 2:23-35.
17. Brendza RP, O'Brien C, Simmons K, McKeel DW, Bales KR, Paul SM, et al. PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic and synaptic structures. J Comp Neurol 2003; 456:375-83.
18. Switzer RC, 3rd. Application of silver degeneration stains for neurotoxicity testing. Toxicol Pathol 2000; 28:70-83.
19. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60:543-54.
20. Graybiel AM. Habits, rituals and the evaluative brain. Annu Rev Neurosci 2008; 31:359-87.
21. Martin S, van den Buuse M. Phencyclidine-induced locomotor hyperactivity is enhanced in mice after stereotaxic brain serotonin depletion. Behav Brain Res 2008; 191:289-93.
22. Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 2005; 46:65-74.
23. Vidal C, Herzog C, Haeberle AM, Bombarde C, Miquel MC, Carimalo J, et al. Early dysfunction of central 5-HT system in a murine model of bovine spongiform encephalopathy. Neuroscience 2009; 160:731-43.
24. Guentchev M, Hainfellner JA, Trabattoni GR, Budka H. Distribution of parvalbumin-immunoreactive neurons in brain correlates with hippocampal and temporal cortical pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1997; 56:1119-24. (Pubitemid 27430473)
25. Belichenko PV, Miklossy J, Belser B, Budka H, Celio MR. Early destruction of the extracellular matrix around parvalbumin-immunoreactive interneurons in Creutzfeldt-Jakob disease. Neurobiol Dis 1999; 6:269-79.
26. Avale ME, Faure P, Pons S, Robledo P, Deltheil T, David DJ, et al. Interplay of beta2* nicotinic receptors and dopamine pathways in the control of spontaneous locomotion. Proc Natl Acad Sci USA 2008; 105:15991-6.
27. Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, et al. Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci 2010; 30:9877-89.
28. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, et al. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha6 nicotinic acetylcholine receptors. Neuron 2008; 60:123-36.
29. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009; 10:211-23.
30. O'Neil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, et al. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat 2007; 34:102-7.
31. Bruce ME, Fraser H. Scrapie strain variation and its implications. Current Topics in Microbiology and Immunology 1991; 172:125-38.
32. Dell'Omo G, Vannoni E, Vyssotski AL, Di Bari MA, Nonno R, Agrimi U, et al. Early behavioural changes in mice infected with BSE and scrapie: automated home cage monitoring reveals prion strain differences. Eur J Neurosci 2002; 16:735-42.
33. Jhuang H, Garrote E, Yu X, Khilnani V, Poggio T, Steele AD, et al. Automated home-cage behavioral phenotyping of mice. Nature Communications 2010; 1:68.
34. Ayers JI, Kincaid AE, Bartz JC. Prion strain targeting independent of strain-specific neuronal tropism. J Virol 2009; 83:81-7.
35. Bessen RA, Marsh RF. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 1992; 66:2096-101.
36. Bessen RA, Marsh RF. Identification of two biologically distinct strains of transmissible mink encephalopathy in hamsters. J Gen Virol 1992; 73:329-34.
37. Cunningham C, Deacon RM, Chan K, Boche D, Rawlins JN, Perry VH. Neuropathologically distinct prion strains give rise to similar temporal profiles of behavioral deficits. Neurobiol Dis 2005; 18:258-69. (Pubitemid 40431109)
38. Sano H, Yasoshima Y, Matsushita N, Kaneko T, Kohno K, Pastan I, et al. Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function. J Neurosci 2003; 23:9078-88.
39. Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity and impaired oral behavior. Proc Natl Acad Sci USA 2007; 104:4182-7.
40. Unger EL, Eve DJ, Perez XA, Reichenbach DK, Xu Y, Lee MK, et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis 2006; 21:431-43.
41. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, et al. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background and developmental adaptations. J Neurosci 1998; 18:3470-9. (Pubitemid 28186038)
42. Smits SM, Noorlander CW, Kas MJ, Ramakers GM, Smidt MP. Alterations in serotonin signalling are involved in the hyperactivity of Pitx3-deficient mice. Eur J Neurosci 2008; 27:388-95.
43. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96:10483-8.
44. Gray BC, Siskova Z, Perry VH, O'Connor V. Selective presynaptic degeneration in the synaptopathy associated with ME7-induced hippocampal pathology. Neurobiol Dis 2009; 35:63-74.
45. Siskova Z, Mahad DJ, Pudney C, Campbell G, Cadogan M, Asuni A, et al. Morphological and functional abnormalities in mitochondria associated with synaptic degeneration in prion disease. Am J Pathol 2010; 177:1411-21.
46. Siskova Z, Page A, O'Connor V, Perry VH. Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol 2009; 175:1610-21.
47. Siskova Z, Sanyal NK, Orban A, O'Connor V, Perry VH. Reactive hypertrophy of synaptic varicosities within the hippocampus of prion-infected mice. Biochem Soc Trans 2010; 38:471-5.
48. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32.
49. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30:6367-74.
50. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 2010; 285:26377-83.
51. Kellett KA, Hooper NM. Prion protein and Alzheimer disease. Prion 2009; 3:190-4.
52. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010; 107:2295-300.
53. Steele AD, Zhou Z, Jackson WS, Zhu C, Auluck P, Moskowitz MA, et al. Context dependent neuroprotective properties of prion protein (PrP). Prion 2009; 3:240-9.
54. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010; 2:306-14.
55. Jeong BH, Lee KH, Jeong YE, Hwang KA, Lee YJ, Carp RI, et al. Polymorphisms at codons 129 and 219 of the prion protein gene (PRNP) are not associated with sporadic Alzheimer's disease in the Korean population. Eur J Neurol 2007; 14:621-6.
56. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 2010; 123:1191-201.
57. Steele AD, Jackson WS, King OD, Lindquist S. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci USA 2007; 104:1983-8.
58. de Olmos JS, Beltramino CA, de Olmos de Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia and physical trauma. Neurotoxicol Teratol 1994; 16:545-61.
59. Gundersen HJ, Jensen EB, Kieu K, Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. J Microsc 1999; 193:199-211.
60. Manaye KF, Wang PC, O'Neil JN, Huang SY, Xu T, Lei DL, et al. Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology and biochemistry. Age (Dordr) 2007; 29:87-96.